Source: Photo.com
On December 21, according to the National Bureau of Disease Control and Prevention, as of December 10, a total of seven cases of the JN.1 variant had been monitored in mainland China. What is the origin of the JN.1 variant introduced into China?
Lu Hongzhou, director of the National Clinical Research Center for Infectious Diseases and president of the Third People's Hospital of Shenzhen, said that the JN.1 mutant strain is a subclade of the new coronavirus Omicron variant BA.2.86, and compared with BA.2.86, the receptor-binding region (RBD region) of the JN.1 variant has an additional L455S mutation. Recent studies have found that the L455S mutation of the JN.1 mutant strain further enhances its immune evasion ability.
In addition, on December 19, local time, the World Health Organization (WHO) issued a preliminary risk assessment, and in view of the rapid spread of the new coronavirus variant JN.1 around the world, it was separately listed as a "variant of interest" (VOI).
Jiang Qingwu, an epidemiologist and professor at Fudan University's School of Public Health, said, "What I'm worried about is that this wave is mainly influenza, and the new coronavirus infection is at a low level of epidemic. However, according to the previous transmission pattern and epidemic characteristics of the new coronavirus, in late December and January, we need to be highly vigilant that the new coronavirus will affect us again. At present, there are countries where the spread of the new crown is far more active than ours. Jiang Qingwu said that it is recommended to actively prepare for the prevention and control of respiratory infectious diseases.
It is worth mentioning that as of December 20, Singapore has opened two "new crown diagnosis and treatment facilities", which are similar to the layout and admission principles of "mobile hospitals". According to Singapore's Ministry of Health, the two facilities currently have a capacity of more than 80 patients and will be further expanded to accommodate more than 100 beds if necessary.
The industrial map of the global "new crown special drug" industry
The main players in the "new crown drug" industry are AstraZeneca, Pfizer, Eli Lilly and Company, Kintor Pharmaceuticals, Merck, Real Biotech, Brii Biosciences, Celltrion, Roche, Gilead, etc., and it is worth noting that some companies such as Pfizer and Kintor Pharmaceuticals also have the ability to produce their intermediates and APIs. Key players in upstream intermediates and APIs include Kintor Pharmaceutical, Junshi Biosciences, Huateng Pharmaceutical, AbbVie, CODEXIS, Zenara Pharma and Pfizer. Players in the CXO field of "COVID-19 drugs" include novasep, Huahai Pharmaceutical, and Asymchem, for example, Pfizer entrusted Huahai Pharmaceutical to be responsible for the production of nirmatrelvir preparations and complete the combination packaging.
China is the most popular place to register companies under development
Most of the global "new crown drug" research companies are registered in China, but not all of these companies in China are local Chinese enterprises, and almost half of the enterprises are foreign-funded enterprises stationed in China. This is followed by the United States and Japan, with 9 and 8 companies under research respectively.
Li Tong, chief physician of the Department of Infectious Diseases of Beijing You'an Hospital, said that although the number of cases is declining, there are still a variety of pathogens that are common to the epidemic, and it is still possible to be infected with other diseases after being infected with a respiratory disease, so it is necessary to take good precautions, once there are symptoms, you should rest at home, and do not go to work and school with illness. When going out, especially in high-risk places such as public transportation or hospitals, shopping malls, etc., wear a mask, reduce the time you stay, and wash your hands in a timely manner. When you are in contact with others, pay attention to cough etiquette and maintain a reasonable social distance to reduce the risk of infection.
Jin Dongyan, a professor at the School of Biomedical Sciences and an expert in virology at the Li Ka Shing Faculty of Medicine of the University of Hong Kong, suggested that the public should get vaccinated in a timely manner, avoid going to crowded places, wear masks, pay attention to hand hygiene, wash hands frequently with running water, keep indoor air circulation and ventilation, ensure adequate sleep and moderate exercise, enhance physical fitness, eat a healthy diet, and eat more foods rich in protein and vitamins.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "Market Prospect and Investment Strategic Planning Analysis Report of China's New Coronary Oral Drug Industry" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certification, IPO consulting/fundraising feasibility study, IPO working paper consulting, etc. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers.